iSpecimen Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that iSpecimen Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.93M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $9.29M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $9.93M | Apr 14, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $9.93M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $10.40M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $11.14M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.18M | Mar 22, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.49M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($12.50M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($11.10M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($10.25M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($8.96M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($4.65M) | Mar 22, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.98M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($12.73M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($11.17M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($10.19M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($5.93M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($2.41M) | Mar 22, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.49M | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | $1.62M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.47M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $879.2K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $319.2K | Mar 22, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.24M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($8.26M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($5.81M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($5.82M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($10.67M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($288.4K) | Mar 22, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $454 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $31.5K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $19.5K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $215.5K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.6K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $426 | Mar 22, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.53M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $9.35M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $15.82M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $24.62M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $35.72M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.21M | Mar 22, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.44M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $6.04M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $6.08M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $4.31M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $5.93M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $22.31M | Mar 22, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.09M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $3.31M | Apr 1, 2026 |
| FY2025 | Dec 31, 2023 | $9.74M | Apr 1, 2026 |
| FY2024 | Dec 31, 2022 | $20.31M | Apr 14, 2025 |
| FY2023 | Dec 31, 2021 | $29.79M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($27.28M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($22.72M) | Mar 22, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($82.35M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($71.86M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($59.36M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($48.27M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($38.02M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($29.06M) | Mar 22, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.88M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $1.88M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $2.34M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $15.31M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $27.74M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $695.9K | Mar 22, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $3.42M | Mar 22, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (17) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (24) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (4) | Mar 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (17) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (24) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (4) | Mar 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.48M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 1.70M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 454,169 | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | 8.93M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 8.73M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 936,213 | Mar 22, 2022 |